ArticleCancer medicine2026
Prediction of Chemotherapy Toxicity After Four Cycles of R-CHOP Treatment for Diffuse Large B-Cell Lymphoma: Effective Imaging Biomarkers of Body Composition.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Computational QSAR and structure-based identification of plerixafor-derived PIM-1 kinase inhibitors in diffuse large B-Cell lymphoma.Frontiers in chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious studies have indicated that diffuse large B-cell lymphoma (DLBCL) patients with a low baseline skeletal muscle (SM) area are more susceptible to severe toxicity during chemotherapy. However, the predictive role of baseline body composition in determining toxicity risk during the initial frontline treatment remains unexplored. This study aims to identify reliable, non-invasive biomarkers and validate findings using follow-up CT scans after four cycles of chemotherapy.
methodsWe retrospectively included DLBCL patients who received four cycles of R-CHOP treatment between January 2015 and January 2024, with pre-treatment abdominal CT scans. We measured the volume, area, and density of SM, visceral adipose tissue (VAT), and subcutaneous adipose tissue (SAT) to assess their predictive potential for chemotherapy toxicity. Subgroup analyses examined longitudinal changes in body composition, and a logistic regression model identified effective imaging biomarkers associated with grade 3/4 toxicity.
resultsAmong the 179 DLBCL patients (mean age 56.96 ± 13.49 years), 46.9% experienced grade 3/4 toxicity. Lower baseline SM volume and density significantly increased the risk of toxicity, particularly in overweight or obese patients (p < 0.05). ROC analysis identified SM volume as the best predictor, with a cutoff of 2093.71 cm
conclusionLower baseline SM volume and its reductions during treatment are associated with an increased risk of grade 3/4 toxicity, particularly in overweight or obese patients. Body composition measurements serve as effective imaging biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.